104 related articles for article (PubMed ID: 19416725)
1. Activation of NFAT signal by p53-K120R mutant.
Shinmen N; Koshida T; Kumazawa T; Sato K; Shimada H; Matsutani T; Iwadate Y; Takiguchi M; Hiwasa T
FEBS Lett; 2009 Jun; 583(12):1916-22. PubMed ID: 19416725
[TBL] [Abstract][Full Text] [Related]
2. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
3. Ser392 phosphorylation regulates the oncogenic function of mutant p53.
Yap DB; Hsieh JK; Zhong S; Heath V; Gusterson B; Crook T; Lu X
Cancer Res; 2004 Jul; 64(14):4749-54. PubMed ID: 15256442
[TBL] [Abstract][Full Text] [Related]
4. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
5. Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation.
Ohata H; Ota N; Shirouzu M; Yokoyama S; Yokota J; Taya Y; Enari M
J Mol Biol; 2009 Dec; 394(3):460-71. PubMed ID: 19766654
[TBL] [Abstract][Full Text] [Related]
6. p53 phosphorylation mutants retain transcription activity.
Fuchs B; O'Connor D; Fallis L; Scheidtmann KH; Lu X
Oncogene; 1995 Feb; 10(4):789-93. PubMed ID: 7862459
[TBL] [Abstract][Full Text] [Related]
7. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
[TBL] [Abstract][Full Text] [Related]
8. Structure and functionality of a designed p53 dimer.
Davison TS; Nie X; Ma W; Lin Y; Kay C; Benchimol S; Arrowsmith CH
J Mol Biol; 2001 Mar; 307(2):605-17. PubMed ID: 11254385
[TBL] [Abstract][Full Text] [Related]
9. Restoration of the transcription activation function to mutant p53 in human cancer cells.
Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
[TBL] [Abstract][Full Text] [Related]
10. Distinct pattern of p53 phosphorylation in human tumors.
Minamoto T; Buschmann T; Habelhah H; Matusevich E; Tahara H; Boerresen-Dale AL; Harris C; Sidransky D; Ronai Z
Oncogene; 2001 Jun; 20(26):3341-7. PubMed ID: 11423984
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
12. Role of phosphorylation in p53 acetylation and PAb421 epitope recognition in baculoviral and mammalian expressed proteins.
Warnock LJ; Raines SA; Mee TR; Milner J
FEBS J; 2005 Apr; 272(7):1669-75. PubMed ID: 15794754
[TBL] [Abstract][Full Text] [Related]
13. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
14. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
[TBL] [Abstract][Full Text] [Related]
15. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
16. Mutations at position 277 modify the DNA-binding specificity of human p53 in vitro.
Chène P
Biochem Biophys Res Commun; 1999 Sep; 263(1):1-5. PubMed ID: 10486243
[TBL] [Abstract][Full Text] [Related]
17. Interaction of heterogeneous nuclear ribonucleoprotein C1/C2 with a novel cis-regulatory element within p53 mRNA as a response to cytostatic drug treatment.
Christian KJ; Lang MA; Raffalli-Mathieu F
Mol Pharmacol; 2008 May; 73(5):1558-67. PubMed ID: 18296503
[TBL] [Abstract][Full Text] [Related]
18. The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning.
Golubovskaya VM; Finch R; Zheng M; Kurenova EV; Cance WG
Biochem J; 2008 Apr; 411(1):151-60. PubMed ID: 18215142
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between site-specific modifications on p53 and histone H3.
Warnock LJ; Adamson R; Lynch CJ; Milner J
Oncogene; 2008 Mar; 27(11):1639-44. PubMed ID: 17891183
[TBL] [Abstract][Full Text] [Related]
20. HBV DNA can bind to P53 protein and influence p53 transactivation in hepatoma cells.
Qu J; Lin J; Zhang S; Zhu Z; Ni C; Zhang S; Gao H; Zhu M
Biochem Biophys Res Commun; 2009 Aug; 386(3):504-9. PubMed ID: 19540192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
